New Systemic Treatments for Prurigo Nodularis

Melodie Young, MSN, A/GNP-C, discusses how the FDA-approved systemic treatments for prurigo nodularis, dupilumab and nevolizumabnemolizumab, differ in their mechanisms of action—dupilumab targeting IL-4 and IL-13, and nevolizumabnemolizumab targeting IL-31—and highlights their similar efficacy in reducing pruritus and lesion size, while also considering differences in safety profiles and treatment considerations.